National Advisory Council Agenda

138th Meeting of the National Advisory Council on Drug Abuse

Virtual Meeting – May 11, 2021

Closed Session

This meeting is closed to the public in accordance with the provisions set forth in section 552b{c}(4) and 552b{c}(6), Title 5, U.S. Code and section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2). 

11 a.m – 12:15 a.m

Time Presentation
11:00 a.m. Call to Order
Nora Volkow, M.D.
Director, NIDA

Review of Policy and Procedures
Susan Weiss, Ph.D.
Executive Secretary
National Advisory Council on Drug Abuse
Director, Division of Extramural Research, NIDA
11:15 a.m.

Council Review of Grant Applications
Nora Volkow, M.D., Director, NIDA

Office of Research Training, Diversity, and Disparities (ORTDD)
Albert Avilla, Ph.D., Deputy Director

Division of Epidemiology, Services, and Prevention Research (DESPR)
Carlos Blanco, M.D., Ph.D., Director

Office of Translational Initiatives and Program Innovationa (OTIPI)
Elena Koustova, Ph.D., M.B.A., Director

Division of Therapeutics and Medical Consequences (DTMC)
Kurt Rasmussen, Ph.D., Director

Division of Neuroscience and Behavior (DNB)
Rita Valentino, Ph.D., Director
12:15 p.m. Brief Break

Videocast:

Members of the public who may wish to express views regarding any items discussed during this meeting may do so by writing Dr. Gillian Acca, within ten days of the meeting.  Any written statements by members of the public will receive careful consideration.

https://videocast.nih.gov/watch=41901

Open Session

12:45 - 4:30 p.m.

Agenda to follow

Time Presentation
12:45 p.m. Welcome and Opening Remarks
Nora Volkow, M.D., Director, NIDA
1:00 p.m. Director's Report
Nora Volkow, M.D., Director, NIDA
1:50 p.m. Discussion
Council Members
2:10 p.m. NIDA-Intramural Research Program – Progress in a Pandemic
Amy Newman, Ph.D., Scientific Director, NIDA IRP
2:40 p.m. Update on NIDA Anti-Harassment and Racial Equity Initiatives
Joellen Austin, MPAff, MSM
Executive Officer, NIDA
Will Aklin, Ph.D., 
Co-Chair, NIDA Racial Equity Initiative
3:10 p.m. DTMC Workgroup Updates
Kurt Rasmussen, Ph.D.
Director, DTMC

CTN Workgroup Updates
Dennis McCarty, Ph.D.
Oregon Health Science University,
CTN Workgroup Member
3:40 p.m. Concept Clearances​
  • Division of Epidemiology, Services, and Prevention Research (DESPR)
    • Accelerating the Pace of Drug Abuse Research Using Existing Data – Marsha Lopez, Ph.D., MHS, Chief, Epidemiology Research Branch
    • Mechanism for Time-Sensitive Drug Abuse Research – Marsha Lopez, Ph.D., MHS, Chief, Epidemiology Research Branch
    • Social Determinants of Opioid Use: Opportunities for Community- and System-Level Interventions – Aria Crump, Sc.D., Deputy Branch Chief, Prevention Research
    • Implementing Comprehensive HIV Services in Syringe Service Program (SSP) Settings – Richard Jenkins, Ph.D., Health Scientist Administrator
    • Stimulants and HIV: Addressing Contemporary and Recurring Epidemics – Richard Jenkins, Ph.D., Health Scientist Administrator
    • Increasing Immediate Engagement and Retention in HIV Treatment with Substance Users – Minnjuan Flournoy Floyd, Ph.D., Social and Behavioral Science Administrator
  • Division of Neuroscience and Behavior (DNB)
    • Pharmacokinetics and Pharmacodynamics of Cannabis and Cannabis-derived Products/Substances – Kiran Vemuri, Ph.D., Health Scientist Administrator
    • HEAL Initiative: Novel Targets for Opioid Use Disorders and Opioid Overdose – Sam Ananthan, Ph.D., Branch Chief, Chemistry, Pharmacology and Physiology
    • Human Post-mortem Brain Resources for Molecular HIV and SUD Research – John Satterlee, Ph.D., Health Scientist Administrator
    • HIV, SUD and Neuropathology at Blood Brain Barrier – Da-Yu Wu, Ph.D., Health Scientist Administrator
    • Investigating Transposable Elements and Mobile DNA as Targets of Integration for Establishing HIV Reservoirs in the Brain – Amy Lossie, Ph.D., Health Scientist Administrator
  • Division of Therapeutics and Medical Consequences (DTMC)
    • Fentanyl and Its Analogs: Effects and Consequences for Treatment of Addiction and Overdose – Aidan Hampson, Ph.D., Health Scientist Administrator
4:15 p.m. Public Comments
4:30 p.m. Adjourn